Abstract
Clinical guidelines recommend the use of erythropoietin-stimulating agents (ESA) in anemic patients with lower risk myelodysplastic syndrome (MDS)[1][1]–[4][2] and two registration trials for ESA have just been completed.[5][3],[6][4] We conducted a retrospective study in MDS patients selected by
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
